drugset

drugset / Trial / NCT05161390

Study of LM-302 in Patients With Advance Solid Tumors

NCT05161390 ↗

Phase 1/2 Completed 153 enrolled LaNova Medicines Zhejiang Co., Ltd.

Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase I/II Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors

Timeline

Start: 2021-11-26
Primary completion: 2025-01-10
Completion: 2025-01-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TPX4589	Other / unclassified	—	—

Indications